Oncolytic viruses: The tiny warriors fighting brain cancer
Oncolytic viruses, once considered medical curiosities, are now cutting-edge tools in the fight against some of the most ...
China’s modified virus therapy shows promise in last-stage cancer trials
A new cancer therapy utilising a genetically modified herpes simplex virus type 1 (HSV-1) offers hope for late-stage patients ...
CURE3d
Progress Reported in Phase 1 Trial of CLD-101 for Recurrent Glioma
A progress report for a phase 1 trial of CLD-101 in recurrent glioma shows safety and feasibility at multiple intracerebral ...
Tumour meltdown in China therapy tests offers hope to late-stage cancer patients
Experimental therapy uses a modified virus to boost immunity and make anti-tumour treatments more effective, according to ...
pharmaphorum2d
Oncolytics: the dawn of a new era in cancer treatment
Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunotherapy.
Fierce Biotech3d
Candel's lung cancer survival data light path toward pivotal trial in subpopulation
Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...
pharmaphorum2d
First launch for Daiichi Sankyo's oncolytic virus Delytact in Japan
Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in ...